For thirty years, pancreatic cancer has occupied a particular place in medicine's imagination — not merely as a deadly disease, but as proof that some walls cannot be moved. This week, researchers announced that an oral drug called daraxonrasib nearly doubled survival time in patients with advanced pancreatic cancer, by successfully targeting a genetic mutation long considered impossible to treat. The achievement, presented at a major oncology conference and published in the New England Journal of Medicine, does not promise a cure — but it does suggest that one of medicine's most stubborn fron
Daraxonrasib Doubles Survival in Advanced Pancreatic Cancer, Offering Rare Hope
Pancreatic cancer kills over 52,000 Americans annually with only 13% five-year survival rate; this drug offers extended survival for patients with previously untreatable advanced disease.
Doubling survival while maintaining quality of life
Mark
Why does it matter that this is an oral pill rather than intravenous chemotherapy?
Mimi
Because patients can take it at home, on their own schedule. Chemotherapy requires hospital visits, infusions, more disruption to what remains of their life. An oral drug also tends to have a different side-effect profile—less acute toxicity, more manageable at home.
Mark
The survival numbers—13.2 months versus 6.7 months—those still sound short. Why is this being called transformative?
Mimi
Because for patients whose cancer has already beaten chemotherapy, six months was the floor. You were essentially out of options. Doubling that time, while also improving quality of life, is the difference between a few months with your family and over a year. In pancreatic cancer, that's not incremental. That's a new category of outcome.
Mark
What was the barrier to targeting KRAS before?
Mimi
The protein's structure made it nearly impossible to design a drug that could bind to it effectively. Scientists tried for decades. It was considered a fundamental limitation of chemistry and biology. Daraxonrasib solved that by finding a binding mechanism that works across multiple KRAS mutation subtypes—it's an engineering breakthrough as much as a medical one.
Mark
Are there risks that this becomes overhyped?
Mimi
Yes. This drug works for patients with a specific stage of disease—metastatic, treatment-resistant. It's not for everyone with pancreatic cancer. And it's not a cure. But within its population, the evidence is solid. The real question now is whether it works even better when used earlier, or combined with other drugs.
Mark
What happens next?
Mimi
FDA review, likely approval. Then researchers test it in earlier stages of disease, in combination with other therapies, in different patient populations. And other companies are racing to develop their own KRAS inhibitors. This is the beginning of a pipeline, not the end of the story.
Il Polso
- Pancreatic cancer kills more than 52,000 Americans each year, and patients whose disease returns after initial treatment have historically survived only five or six months — a grim arithmetic that has barely changed in decades.
- The KRAS gene mutation, present in over 90% of pancreatic cancers, was long dismissed as 'undruggable,' making the disease resistant to the targeted therapies that transformed outcomes in lung, breast, and melanoma.
- Daraxonrasib's novel molecular binding mechanism cracks that barrier, attaching to multiple KRAS mutation subtypes and blocking their tumor-promoting activity — a solution to a problem many researchers had stopped believing was solvable.
- In a phase III trial of roughly 500 patients, those taking the daily pill survived a median of 13.2 months compared to 6.7 months on standard chemotherapy, while also reporting better quality of life and fewer severe side effects.
- The FDA is expediting its review, expanded access is already underway, and researchers are now testing the drug in earlier disease stages and in combination therapies — with several other KRAS-targeting agents advancing through the pipeline behind it.
For thirty years, pancreatic cancer has occupied a particular place in medicine's imagination — not merely as a deadly disease, but as proof that some walls cannot be moved. This week, researchers announced that an oral drug called daraxonrasib nearly doubled survival time in patients with advanced pancreatic cancer, by successfully targeting a genetic mutation long considered impossible to treat. The achievement, presented at a major oncology conference and published in the New England Journal of Medicine, does not promise a cure — but it does suggest that one of medicine's most stubborn frontiers is, at last, beginning to yield.
For decades, pancreatic cancer has been the disease that resists everything. It arrives late, spreads fast, and when it returns after initial treatment, the options narrow to almost nothing. That calculus shifted this week.
Researchers announced that daraxonrasib, a daily oral pill, nearly doubled survival time in patients with advanced pancreatic cancer that had stopped responding to prior chemotherapy. In a phase III trial of roughly 500 patients, those taking the drug survived a median of 13.2 months — compared to 6.7 months for those on standard chemotherapy. The findings were presented at the American Society of Clinical Oncology annual meeting in Chicago and published simultaneously in the New England Journal of Medicine.
The breakthrough centers on a target long considered untouchable. More than 90 percent of pancreatic cancers carry mutations in the KRAS gene, which drives uncontrolled tumor growth. For years, KRAS was described within oncology as 'undruggable' — structurally too difficult to interfere with. Daraxonrasib overcomes that barrier through a binding mechanism that attaches to multiple KRAS mutation subtypes and blocks their cancer-promoting activity, representing a new generation of therapies built to solve what had seemed unsolvable.
The human stakes are considerable. The American Cancer Society projects more than 52,000 pancreatic cancer deaths in the United States this year, with a five-year survival rate of just 13 percent — a figure that has barely moved despite decades of aggressive chemotherapy. Most patients are diagnosed only after the disease has already spread, leaving them with few options when initial treatment fails.
Beyond survival time, the trial showed additional advantages. Patients on daraxonrasib reported better quality of life and lower pain levels than those on chemotherapy, and the drug's side-effect profile — primarily skin rash and mouth sores — compared favorably with conventional treatment. Many patients were still taking the drug when the data were analyzed, suggesting survival benefits may grow with longer follow-up.
The FDA is expected to expedite its review, and eligible patients are already being granted access through the agency's expanded-access program. Researchers are exploring earlier use of the drug — before surgery or alongside other therapies — and several other KRAS-targeting agents are advancing through the development pipeline. For a disease that has lagged behind others in the era of targeted medicine, the landscape is beginning, carefully, to change.
For decades, pancreatic cancer has been the oncologist's wall. The disease arrives late, spreads fast, and resists the drugs that work elsewhere. When it returns after initial treatment, the options narrow to almost nothing. Patients typically survive another five or six months. That calculus has just shifted.
Researchers announced this week that an oral medication called daraxonrasib nearly doubled survival time in patients with advanced pancreatic cancer that had stopped responding to prior chemotherapy. In a phase III trial of roughly 500 patients, those taking the daily pill survived a median of 13.2 months, compared to 6.7 months for those receiving standard chemotherapy. The findings, presented at the American Society of Clinical Oncology annual meeting in Chicago and published simultaneously in the New England Journal of Medicine, represent what cancer specialists are calling a potentially transformative moment for a disease that has resisted progress for thirty years.
The breakthrough hinges on a molecular target that was long considered impossible to hit. More than 90 percent of pancreatic cancers carry mutations in the KRAS gene, which drives uncontrolled tumor growth. For decades, KRAS was described within the oncology community as "undruggable"—a protein so structurally difficult to interfere with that many researchers believed it could never be successfully targeted with medication. Daraxonrasib overcomes that barrier through a molecular binding mechanism that allows it to attach to multiple KRAS mutation subtypes and block their cancer-promoting activity. The drug represents a new generation of targeted therapies designed specifically to solve a problem that had seemed unsolvable.
The human stakes are substantial. The American Cancer Society projects roughly 67,000 new pancreatic cancer diagnoses in the United States this year, with more than 52,000 deaths. The five-year survival rate stands at just 13 percent—a figure that has barely budged despite aggressive multi-drug chemotherapy. Pancreatic cancer is notorious for presenting with vague symptoms in its early stages, meaning most patients are diagnosed only after the disease has already spread to other organs. For those whose cancer progresses despite initial treatment, the landscape of available options has been bleak. Daraxonrasib changes that calculus, at least for this subset of patients.
Beyond the survival numbers, the trial revealed other advantages. Patients on daraxonrasib reported better quality of life and lower pain levels than those receiving chemotherapy. Tumor shrinkage was observed in a substantial proportion of patients. The drug's side-effect profile also compared favorably with conventional chemotherapy—the most common adverse effects were skin rash and mouth sores, though some cases required dose adjustments. Patients remained on treatment significantly longer than those receiving chemotherapy, and many were still taking the drug when the data were analyzed, suggesting that survival benefits could increase further with longer follow-up.
Oncologists emphasize that while the absolute numbers may not seem dramatic to the lay reader, the context makes them extraordinary. An oral tablet that nearly doubles survival in a disease this aggressive, administered to patients who have already exhausted their first-line options, represents a genuine shift in what was previously possible. The drug is not a cure. But it is direct evidence that targeting KRAS can meaningfully alter the course of a disease that has remained stubbornly resistant to treatment.
The U.S. Food and Drug Administration is expected to expedite its review of daraxonrasib. Meanwhile, eligible patients are being granted access through the agency's expanded-access program. Researchers are already exploring whether the drug could be used earlier in the disease course—before surgery or in combination with other therapies. The success of daraxonrasib has also catalyzed broader momentum in pancreatic cancer research. Several other KRAS-targeting drugs are currently in development, while researchers are testing personalized vaccines and immunotherapy-based strategies aimed at preventing recurrence after surgery. For a disease that has lagged behind lung, breast, and melanoma in the development of effective targeted therapies, the pipeline is beginning to fill.
Citazioni salienti
Pancreatic cancer is one of the most difficult cancers to treat. Any therapy that significantly extends survival while maintaining quality of life is an important development.— Dr. Deepak Sundriyal, AIIMS Rishikesh
When an oral tablet almost doubles survival in patients who have already received chemotherapy, there is reason to look for a silver lining.— Dr. Anant Ramaswamy, Tata Memorial Centre, Mumbai
Vuoi la storia completa?
Leggi l'originale su THE WEEK ↗
Health & Medicine